A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Name: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Published: 2020
License: Public Domain

Cabaletta Bio · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

autoimmune-disease autoimmunity cell-therapy immunotherapy

pemphigus vulgaris, pemphigus, caar-t therapy, car-t therapy, desmoglein 3, cell therapy, autoimmune disease, autoimmunity, skin diseases, vesiculobullous, immunotherapy, adoptive, immune system diseases, caba-201

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Related documents